Poolbeg Pharma (POLB) Ord Shares

Sell:2.50pBuy:2.60pNo change

Prices delayed by at least 15 minutes
Sell:2.50p
Buy:2.60p
Change:No change
Prices delayed by at least 15 minutes
Sell:2.50p
Buy:2.60p
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

Poolbeg Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on the development of medicines to address unmet medical needs. Its clinical programmes target addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions, such as obesity with the development of an oral encapsulated glucagon-like peptide (GLP-1R) agonist. Its pipeline includes POLB 001 Oncology, POLB 001 Influenza, AI Programmes and Oral Encapsulated GLP-1programme. POLB 001 is an orally delivered p38 MAP Kinase inhibitor being developed for the prevention of CRS associated with Bispecific Antibodies and CAR T immunotherapy treatments in cancer. It uses artificial intelligence to identify infectious disease drug targets & treatments. The Oral Encapsulated GLP-1 programme leverages an advanced delivery system that encapsulates active pharmaceutical ingredients using Generally Regarded as Safe (GRAS) components.

Key people

Cathal Martin Friel
Executive Chairman of the Board
Jeremy Skillington
Chief Executive Officer, Executive Director
Ian Oconnell
Chief Financial Officer, Executive Director
Brendan Mary Buckley
Independent Non-Executive Director
Eddie Gibson
Independent Non-Executive Director
Luke Oneill
Independent Non-Executive Director
Click to see more

Key facts

  • EPIC
    POLB
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB00BKPG7Z60
  • Market cap
    £17.78m
  • Employees
    10
  • Shares in issue
    697.20m
  • Exchange
    London Stock Exchange (LON)
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.